pseudolongum could not exhibit anti-tumor immunity against colon cancer, bladder cancer and melanoma, whereas its combination with anti-CTLA-4 treatment significantly decreases tumor growth compared to anti-CTLA-4 treatment alone by increasing IFN-γ production mediated via higher spleen TH1 cell activation [66]. Here, CTLA4 is linked to urinary bladder cancer.